Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: The SUPER GATE study

Basit Öğe Kaydı
dc.authorid0000-0002-3836-2125en_US
dc.authorid0000-0001-7306-5233en_US
dc.authorid0000-0003-4201-9757en_US
dc.authorid0000-0003-3790-9077en_US
dc.contributor.authorBilgin, Satılmış
dc.contributor.authorKurtkulağı, Özge
dc.contributor.authorDuman, Tuba Taslamacıoğlu
dc.contributor.authorTel, Burçin Meryem Atak
dc.contributor.authorKahveci, Gizem
dc.contributor.authorKıran, Murat
dc.contributor.authorErge, Eray
dc.contributor.authorAktaş, Gülali
dc.date.accessioned2023-05-25T11:06:30Z
dc.date.available2023-05-25T11:06:30Z
dc.date.issued2022en_US
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground Empagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, yielded significant beneficiaries in the treatment of type 2 diabetes mellitus (T2DM). It is particularly benefited the diabetic subjects with heart conditions. Aims We aimed to obtain a real-world data about the effects of empagliflozin add-on treatment on metabolic parameters, cardiovascular risk factors, and anthropometric measures in patients with T2DM. Methods Type 2 diabetic patients with established coronary heart disease whom empagliflozin added to their treatment were enrolled in the study. Anthropometric measures, clinical and laboratory data, were obtained before and at the 6th month of the empagliflozin treatment. All data before and at the 6th month were compared. Results Body weight (p < 0.001), body mass index (p < 0.001), waist (p < 0.001) and hip (p < 0.001) circumferences, systolic blood pressure (p = 0.006), heart rate (p = 0.01), LDL cholesterol (p = 0.01), fasting plasma glucose (p < 0.001), and HbA1c (p < 0.001) levels were significantly reduced on 6th month of empagliflozin treatment compared to the baseline values. Estimated GFR (p = 0.66), serum creatinine (p = 0.8), uric acid (p = 0.40), total cholesterol (p = 0.053), triglyceride (p = 0.057), and HDL (p = 0.09) levels were not significantly changed. Conclusions We suggest that empagliflozin treatment may improve anthropometric measures, metabolic parameters, and blood pressure and does not cause deterioration in kidney functions in type 2 diabetic patients with established coronary heart disease.en_US
dc.identifier.citationBilgin, S., Kurtkulagi, O., Duman, T. T., Tel, B. M. A., Kahveci, G., Kiran, M., ... & Aktas, G. (2022). Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study. Irish Journal of Medical Science (1971-), 191(4), 1647-1652.en_US
dc.identifier.doi10.1007/s11845-021-02761-6
dc.identifier.endpage1652en_US
dc.identifier.issn0021-1265
dc.identifier.issn1863-4362
dc.identifier.issue4en_US
dc.identifier.pmid34476725en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1647en_US
dc.identifier.urihttp://dx.doi.org/10.1007/s11845-021-02761-6
dc.identifier.urihttps://hdl.handle.net/20.500.12491/10962
dc.identifier.volume191en_US
dc.identifier.wosWOS:000692055400002en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorDuman, Tuba Taslamacıoğlu
dc.institutionauthorKıran, Murat
dc.institutionauthorErge, Eray
dc.institutionauthorAktaş, Gülali
dc.language.isoenen_US
dc.publisherSpringer London Ltden_US
dc.relation.ispartofIrish Journal of Medical Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCoronary Heart Diseaseen_US
dc.subjectEmpagliflozinen_US
dc.subjectFasting Glucoseen_US
dc.subjectHba1cen_US
dc.subjectType 2 Diabetes Mellitusen_US
dc.titleSodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: The SUPER GATE studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
satilmis-bilgin.pdf
Boyut:
648.68 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu